Beyond Air (XAIR) AI Stock Analysis

• Market Cap: $12.99M
• Dividend Yield: N/A
• Average Volume (3M): 284.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.71
• Revenue Growth: 219.67%
• EPS Growth: 56.69%
• Country: US
• Employees: 107
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): -1.80
• Shares Outstanding: 4,639,739
• 10 Day Avg. Volume: 135,272
• 30 Day Avg. Volume: 284,191
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 2.30
• Enterprise Value/Revenue: 8.05
• Enterprise Value/Gross Profit: -17.92
• Enterprise Value/Ebitda: -0.71
• 1Y Price Target: $20.75
• Price Target Upside: 641.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 44 Neutral
• Price Target: $3.00 ▲(7.14% Upside)

Beyond Air's overall stock score reflects significant financial challenges, with persistent losses and negative cash flows weighing heavily on its assessment. Despite a positive outlook from recent earnings calls and strategic international expansion, the stock's technical indicators and valuation metrics suggest caution. The company's financial performance is the most critical factor impacting the score, highlighting the need for improved profitability and operational efficiency.

Positive Factors

Financial Performance

3Q25 LungFit PH revenue of $1.1M was above estimate of $0.88M, with revenue up 34% quarter-over-quarter and 174% year-over-year.

Partnerships

Beyond Air announced an agreement with Premier, Inc., allowing Premier members to acquire LungFit PH Smart Filters with special pricing and pre-negotiated terms.

Product Development

The transport-ready LungFit PH system is expected to rapidly match and surpass the commercial adoption of GENOSYL, indicating strong market potential.

Negative Factors

Commercial Challenges

Beyond Air faced setbacks and challenges in its initial commercial efforts, which limited its ability to achieve substantial revenue due to delays and disruptions during the COVID-19 pandemic and a failed agreement with a partner.

Regulatory Review

PMA supplement to expand label to include certain cardiac surgeries is under review at the FDA.

Beyond Air Business Overview & Revenue Model

Company Description

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

How the Company Makes Money

Beyond Air generates revenue primarily through the commercialization of its LungFit™ platform, which delivers nitric oxide for treating respiratory conditions such as bronchiolitis and chronic obstructive pulmonary disease (COPD). The company aims to monetize its technology by obtaining regulatory approvals, launching its devices in key markets, and establishing partnerships with healthcare providers and distributors. Beyond Air's revenue model focuses on selling or leasing its devices to hospitals and clinics, as well as potentially earning royalties or licensing fees from strategic partnerships. Additionally, the company invests in research and development to expand the therapeutic applications of its platform and enhance its market potential.

Beyond Air Financial Statement Overview

Summary

Beyond Air is facing notable financial challenges with persistent losses and negative cash flows. Despite some revenue growth, profitability remains elusive, and the company's reliance on debt highlights potential financial risks. The balance sheet and cash flow statements suggest the need for strategic financial management to improve sustainability and operational efficiency.

Income Statement

Beyond Air shows a challenging financial performance with consistent net losses over the years. The gross profit margin and net profit margin are negative, indicating the company is not covering its costs with its revenue. Revenue growth is volatile, with significant increases in 2024 and 2025, yet it remains insufficient to offset operating losses. The EBIT and EBITDA margins are also negative, highlighting operational inefficiencies.

Balance Sheet

The company has a high debt-to-equity ratio, indicating a reliance on debt financing, which could pose risks if revenue growth does not improve. The equity ratio is weakening, and return on equity is negative due to sustained net losses, reflecting poor returns for shareholders. The balance sheet reveals decreasing stockholders' equity and a decline in cash reserves, suggesting financial strain.

Cash Flow

Operating cash flow is consistently negative, reflecting cash outflows from operations. Free cash flow is also negative, though there is a slight improvement from 2024 to 2025. The operating cash flow to net income ratio remains unfavorable, and the free cash flow to net income ratio indicates the company's ongoing struggle to generate cash from its operations.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	3.71M	1.16M	0.00	0.00	873.00K
Gross Profit	-1.66M	-1.31M	-555.00K	-588.00K	873.00K
EBITDA	-41.89M	-59.03M	-58.20M	-42.70M	-22.02M
Net Income	-46.63M	-60.24M	-55.82M	-43.18M	-22.88M
Balance Sheet
Total Assets	30.06M	56.96M	68.75M	99.20M	40.52M
Cash, Cash Equivalents and Short-Term Investments	6.92M	34.47M	45.88M	80.24M	34.63M
Total Debt	11.69M	17.84M	3.59M	3.49M	6.93M
Total Liabilities	15.72M	29.77M	26.72M	20.99M	10.06M
Stockholders Equity	13.58M	25.05M	37.91M	72.70M	30.46M
Cash Flow
Free Cash Flow	-44.10M	-61.76M	-36.89M	-24.58M	-20.53M
Operating Cash Flow	-38.22M	-56.01M	-33.01M	-23.13M	-19.64M
Investing Cash Flow	14.90M	-12.23M	-20.59M	-1.45M	-890.00K
Financing Cash Flow	16.65M	43.17M	2.70M	79.45M	30.33M

Beyond Air Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XAIR, the sentiment is Negative. The current price of 2.8 is below the 20-day moving average (MA) of 3.11, below the 50-day MA of 3.53, and below the 200-day MA of 6.15, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 38.09 is Neutral, neither overbought nor oversold. The STOCH value of 11.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XAIR.

Beyond Air Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FONR	77 Outperform	$99.22M	13.05	5.00%	―	0.29%	-22.13%
SRTS	64 Neutral	$87.65M	48.68	3.46%	―	24.75%	-61.29%
Sector *	51 Neutral	$7.39B	0.36	-62.86%	2.37%	15.48%	-2.68%
INGN	51 Neutral	$170.20M	―	-14.10%	―	5.73%	72.50%
LUNG	45 Neutral	$66.82M	―	-66.88%	―	18.24%	4.81%
XAIR	44 Neutral	$12.99M	―	-241.40%	―	219.67%	56.69%
NNOX	42 Neutral	$311.80M	―	-30.11%	―	15.32%	15.73%

Beyond Air Corporate Events

Beyond Air Implements Reverse Stock Split for Nasdaq Compliance

Beyond Air, Inc. announced a 1-for-20 reverse stock split of its common stock, approved during a special stockholders meeting on June 20, 2025, and effective on July 14, 2025. This move aims to increase the per share bid price above $1.00 to comply with Nasdaq Listing Rule 5550(a)(2). While the reverse stock split will adjust the number of shares held by stockholders, it will not affect the company’s authorized capital stock or the rights of preferred stockholders. The company hopes this action will help regain compliance with Nasdaq requirements, although there is no assurance of achieving the desired effects.

The most recent analyst rating on (XAIR) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.

Beyond Air Approves Reverse Stock Split Proposal

On June 20, 2025, Beyond Air, Inc. held a special meeting of stockholders where a reverse stock split proposal was approved. The proposal grants the board of directors the authority to implement a reverse stock split at a ratio between 1-for-10 and 1-for-50 within a year, potentially impacting the company’s stock structure and market perception.

The most recent analyst rating on (XAIR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.

Beyond Air Appoints Robert Goodman to Board

On June 16, 2025, Beyond Air appointed Robert Goodman to its Board of Directors, bringing his extensive experience in healthcare leadership to the company. Additionally, Beyond Air announced the submission of a premarket approval supplement to the FDA for its second-generation LungFit PH device, which could significantly enhance its market potential. The company reported a 220% increase in annual revenue for the fiscal year ending March 31, 2025, driven by the demand for LungFit PH and international expansion. Despite a net loss, Beyond Air’s strategic moves, including new distribution partnerships and regulatory approvals, position it for a pivotal year ahead.

The most recent analyst rating on (XAIR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.